Shattuck Labs’ (STTK) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Shattuck Labs (NASDAQ:STTK) in a research note released on Thursday, Benzinga reports. The firm currently has a $28.00 target price on the stock.

Separately, Needham & Company LLC reiterated a buy rating and set a $12.00 target price on shares of Shattuck Labs in a research note on Tuesday, April 9th.

Shattuck Labs Stock Down 2.9 %

NASDAQ STTK opened at $10.78 on Thursday. The stock has a market cap of $512.59 million, a PE ratio of -5.59 and a beta of 1.98. Shattuck Labs has a fifty-two week low of $1.33 and a fifty-two week high of $11.62. The business has a 50 day moving average price of $9.42 and a two-hundred day moving average price of $6.95.

Shattuck Labs (NASDAQ:STTK) last released its quarterly earnings results on Thursday, May 2nd. The company reported ($0.37) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.08. The firm had revenue of $1.15 million during the quarter, compared to analysts’ expectations of $0.30 million. Shattuck Labs had a negative return on equity of 64.46% and a negative net margin of 3,133.63%. The business’s quarterly revenue was up 2200.0% on a year-over-year basis. Sell-side analysts anticipate that Shattuck Labs will post -1.85 EPS for the current fiscal year.

Insider Activity at Shattuck Labs

In related news, insider Stephen Stout sold 16,004 shares of the company’s stock in a transaction that occurred on Wednesday, March 6th. The stock was sold at an average price of $10.53, for a total transaction of $168,522.12. Following the sale, the insider now directly owns 74,437 shares of the company’s stock, valued at approximately $783,821.61. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 9.89% of the company’s stock.

Institutional Investors Weigh In On Shattuck Labs

Several institutional investors and hedge funds have recently made changes to their positions in the company. Tower Research Capital LLC TRC raised its position in shares of Shattuck Labs by 79.2% during the 4th quarter. Tower Research Capital LLC TRC now owns 13,553 shares of the company’s stock valued at $97,000 after acquiring an additional 5,989 shares in the last quarter. Cannon Global Investment Management LLC acquired a new stake in Shattuck Labs in the first quarter worth $91,000. Reliant Investment Management LLC acquired a new stake in Shattuck Labs in the fourth quarter worth $143,000. SG Americas Securities LLC acquired a new stake in Shattuck Labs in the fourth quarter worth $268,000. Finally, Pinnacle Associates Ltd. increased its position in Shattuck Labs by 13.9% in the first quarter. Pinnacle Associates Ltd. now owns 521,246 shares of the company’s stock worth $4,660,000 after buying an additional 63,800 shares during the period. 58.74% of the stock is owned by institutional investors and hedge funds.

Shattuck Labs Company Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.